TdC 251: Atualizações no tratamento de obesidade

Ta de Clinicagem

Ciência Fitness Medicamento Ta De Clinicagem Raciocínio Diagnóstico Clinicagem Medicina

Вміст надано Ta de Clinicagem. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Ta de Clinicagem або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.

4M ago 43:40

MP3•Головна епізоду

Iaaaaaaaaago Jorge, Marcela Belleza e Nathalie Santana conversam sobre as últimas atualizações no tratamento da obesidade em três partes: o que é obesidade controlada? quais são as drogas novas? quais são os efeitos adversos?

Use o cupom TDC2024 para assinar o HITT do Medcof e ganhe um cupom de 6 meses gratuitos do Guia TdC!

https://hiit.grupomedcof.com.br

Referências:

1. Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Netw Open. 2024;7(8):e2427258. Published 2024 Aug 1. doi:10.1001/jamanetworkopen.2024.27258

2. Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 2024;16(1):6. Published 2024 Jan 3. doi:10.1186/s13098-023-01233-4

3. Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. Published online July 22, 2024. doi:10.1001/jama.2024.10816

4. Halpern B, Mancini MC, de Melo ME, et al. Proposal of an obesity classification based on weight history: an official document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of

5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

6. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972

7. Li JR, Cao J, Wei J, Geng W. Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023;14:1238353. Published 2023 Aug 29. doi:10.3389/fpsyt.2023.1238353

8. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563

9. Obesity and Metabolic Syndrome (ABESO). Arch Endocrinol Metab. 2022;66(2):139-151. doi:10.20945/2359-3997000000465

10. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. Published online July 8, 2024. doi:10.1001/jamainternmed.2024.2525

11. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population [published correction appears in Nat Commun. 2024 Jun 18;15(1):5177. doi: 10.1038/s41467-024-49655-6]. Nat Commun. 2024;15(1):4548. Published 2024 May 28. doi:10.1038/s41467-024-48780-6

12. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176. doi:10.1038/s41591-023-02672-2

308 епізодів

#Ciência #Fitness #Medicamento #Ta De Clinicagem #Raciocínio Diagnóstico #Clinicagem #Medicina